Santhera acquired the option to in-license the global rights (excluding Japan/South Korea) of vamorolone in all indications, including DMD, from Idorsia (Actelion spin-off), which became an anchor shareholder with a 13.3% stake. Vamorolone complements Santhera’s current DMD program with Raxone, covering all DMD patients, with significant synergies. Santhera now has the potential to become the leader in the DMD market with both products in pivotal development. The company plans an EGM and targeted share placement of 3.5 mn registered shares to raise CHF ~50 mn to finance the vamorolone agreement and ongoing projects. Existing and new shareholders have already committed to ~40% of the placement. Santhera is significantly undervalued compared to other DMD players.
Key catalysts of the updated report (see download below) include:
1. EGM & targeted share placement of CHF ~50 mn (11 December 2018)
2. Raxone EU re-filing in DMD (late Q1 2019)
3. Raxone US filing in DMD (H2 2019)